File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia

TitleCyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia
Authors
KeywordsHigh-risk gestational trophoblastic disease
Chemotherapy
Chamoc regimen
Issue Date2015
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/
Citation
International Journal of Gynecological Cancer, 2015, v. 25, n. 3, p. 498-503 How to Cite?
AbstractCopyright © 2015 by IGCS and ESGO. Objective: The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN). Methods: We conducted a retrospective study of all patients with GTN treated with the CHAMOC regimen between 1985 and 2012 in a tertiary referral center in Hong Kong. Medical records were reviewed, and data were analyzed. Response rate and toxicity profile were assessed. Results: The CHAMOC regimen was given to 79 patients from 1985 to 2012, with a total of 388 cycles administered. Among the 79 patients, CHAMOC was given to 68 as the primary treatment of high-risk GTN, whereas it was used as the salvage chemotherapy in 11 patients for failure with other chemotherapy regimens or recurrent disease. Complete remission was achieved in 58 patients (85.3%) in the primary treatment group and 8 patients (72.7%) in the salvage treatment group. Grade 3 and grade 4 neutropenia were observed in 13.0% and 3.4% of the chemotherapy cycles, respectively. Grade 3 or 4 thrombocytopenia was rare (1.3% of all treatment cycles). No secondary malignancy was observed in our patients with a mean duration of follow-up of 9.7 to 13 years, except 1 patient with advanced colon cancer diagnosed shortly after chemotherapy, which was unlikely to represent a secondary malignancy from the chemotherapy. Conclusions: The CHAMOC regimen should be considered as an alternative to other chemotherapy regimens in the primary treatment of high-risk gestational trophoblastic disease, with comparable efficacy, similar short-term side-effects profile, and potentially fewer long-term complications.
Persistent Identifierhttp://hdl.handle.net/10722/232133
ISSN
2019 Impact Factor: 2.095
2015 SCImago Journal Rankings: 0.830

 

DC FieldValueLanguage
dc.contributor.authorChu, MYM-
dc.contributor.authorMa, Y-
dc.contributor.authorTse, KY-
dc.contributor.authorChan, KKL-
dc.contributor.authorNgan, HYS-
dc.date.accessioned2016-09-20T05:27:57Z-
dc.date.available2016-09-20T05:27:57Z-
dc.date.issued2015-
dc.identifier.citationInternational Journal of Gynecological Cancer, 2015, v. 25, n. 3, p. 498-503-
dc.identifier.issn1048-891X-
dc.identifier.urihttp://hdl.handle.net/10722/232133-
dc.description.abstractCopyright © 2015 by IGCS and ESGO. Objective: The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN). Methods: We conducted a retrospective study of all patients with GTN treated with the CHAMOC regimen between 1985 and 2012 in a tertiary referral center in Hong Kong. Medical records were reviewed, and data were analyzed. Response rate and toxicity profile were assessed. Results: The CHAMOC regimen was given to 79 patients from 1985 to 2012, with a total of 388 cycles administered. Among the 79 patients, CHAMOC was given to 68 as the primary treatment of high-risk GTN, whereas it was used as the salvage chemotherapy in 11 patients for failure with other chemotherapy regimens or recurrent disease. Complete remission was achieved in 58 patients (85.3%) in the primary treatment group and 8 patients (72.7%) in the salvage treatment group. Grade 3 and grade 4 neutropenia were observed in 13.0% and 3.4% of the chemotherapy cycles, respectively. Grade 3 or 4 thrombocytopenia was rare (1.3% of all treatment cycles). No secondary malignancy was observed in our patients with a mean duration of follow-up of 9.7 to 13 years, except 1 patient with advanced colon cancer diagnosed shortly after chemotherapy, which was unlikely to represent a secondary malignancy from the chemotherapy. Conclusions: The CHAMOC regimen should be considered as an alternative to other chemotherapy regimens in the primary treatment of high-risk gestational trophoblastic disease, with comparable efficacy, similar short-term side-effects profile, and potentially fewer long-term complications.-
dc.languageeng-
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/-
dc.relation.ispartofInternational Journal of Gynecological Cancer-
dc.rightsThis is a non-final version of an article published in final form in (provide complete journal citation)-
dc.subjectHigh-risk gestational trophoblastic disease-
dc.subjectChemotherapy-
dc.subjectChamoc regimen-
dc.titleCyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia-
dc.typeArticle-
dc.identifier.emailChu, MYM: chumy@hku.hk-
dc.identifier.emailTse, KY: tseky@hkucc.hku.hk-
dc.identifier.emailChan, KKL: kklchan@hkucc.hku.hk-
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hk-
dc.identifier.authorityMa, Y=rp01539-
dc.identifier.authorityChan, KKL=rp00499-
dc.identifier.authorityNgan, HYS=rp00346-
dc.identifier.doi10.1097/IGC.0000000000000383-
dc.identifier.pmid25628108-
dc.identifier.scopuseid_2-s2.0-84924359759-
dc.identifier.hkuros265873-
dc.identifier.volume25-
dc.identifier.issue3-
dc.identifier.spage498-
dc.identifier.epage503-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats